GNPX News and Press, Genprex Inc. From 02/11/20

February 11, 2020 Palm Beach, FL –February 11, 2020 – The global diabetes drugs market size was valued at USD $48,753.1 Million in 2018, is projected to reach USD 78,261.7 Million by the end of 2026, exhibiting a CAGR of 6.1%, according to industry reports. Rise in obesi...

Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh Results from in vivo animal studies indicate that normal glucose levels in the blood may be restored for an extended period of time Company plans to partner for t...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the ...

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced that it received notice from The Nasdaq Sto...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the u...

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provides a clinical update and focus for its On...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s pre...

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced that the Company will present at the Noble ...

Lee Enterprises (NYSE: LEE ) +55%  to acquire BH Media Group’s publications and  The Buffalo News  for $140M. More news on: Lee Enterprises, Incorporated, Hepion Pharmaceuticals, Inc., Genprex, Inc., Stocks on the move, , Read more ...

Study results show TUSC2 overexpression decreased thyroid cancer tumor metastasis and increased sensitivity to apoptosis by increasing SMAC/DIABLO and Cytochrome C protein levels Study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to...